Montreal, May 24, 2018 (Globe Newswire) – I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, is pleased to announce the signing of a Canadian distribution agreement with ESW Vision for the patented E>Eye device. E>Eye,…
Montreal, April 3, 2018 (Globe Newswire) – I-MED Pharma Inc., a Canadian Company specializing in dry eye diagnosis and management, is pleased to announce receiving regulatory approval from INVIMA in Colombia and ANMAT in Argentina for its patented I-PEN® Osmolarity…
Montreal, February 20, 2018 (GLOBE NEWSWIRE) – On February 14th TearLab issued a press release indicating it will appeal after its defeat in a patent infringement action against I-MED Pharma Inc. in Canada. In the press release, it was stated…
I-MED PHARMA Inc., Your Leader in Ocular Surface Disorder Management, is proud to announce the launch of our new and improved website www.imedpharma.com. This site contains a comprehensive list of all our OSD, diagnostic and surgical product offerings detailing their…
Montreal, February 13, 2018 (GLOBE NEWSWIRE) – I-MED Pharma Inc., announced today that TearLab’s efforts to keep the I-PEN® Osmolarity System off the market proved unsuccessful. I-MED Pharma wins patent case against TearLab, with costs awarded to I-MED. In February…
Montreal, January 8, 2018 (Globe Newswire) – I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, is pleased to announce the signing of an exclusive agreement with OCuSOFT Inc. for distribution rights in the United States…
MONTREAL, January 8, 2018 (GLOBE NEWSWIRE) – I-MED Pharma, Inc., a Canadian company specializing in dry eye diagnosis and management, announced today the signing of an exclusive agreement with IMEX for distribution of its I-PEN® Tear Osmolarity System and I-PLUG® punctum…
Copyright © 2018 I-MED Pharma inc. All rights reserved.
Privacy | Terms & Conditions
